On July 7, 2026, C. Frank Bennett, the Executive Vice President and Chief Scientific Officer of Ionis Pharmaceuticals Inc., completed the sale of common stock totaling approximately $1,744,623. The execution of these sales occurred within a specific price band, ranging from $83.579 to $85.462 per share. The transactions were structured under a Rule 10b5-1 trading plan, which Mr. Bennett adopted on March 31, 2026, indicating a pre-arranged framework for divestment.
The reported activity comprised two distinct categories of share disposal. The first category involved the sale of 5,536 shares of common stock directly owned by Mr. Bennett. These shares were disposed of at a weighted average price of $83.579. The execution of this portion of the sale occurred across multiple transactions, with prices fluctuating between $83.070 and $84.065. This direct sale took place at price levels closely approaching the stock's 52-week high of $86.74. The valuation context is notable given that the stock has delivered a 50% return over the preceding year. Despite this recent appreciation, analysis suggests the stock may currently appear undervalued relative to fair value estimates.
The second category of the transaction involved 15,000 shares of common stock indirectly owned by Mr. Bennett through a trust. These shares were sold at a higher weighted average price of $85.462 per share. The price range for these specific transactions spanned from $85.015 to $85.730. Like the direct sale, this transaction was also executed pursuant to the same Rule 10b5-1 trading plan established in March.
In addition to the sales, other ownership adjustments were reported. Mr. Bennett transferred 15,000 shares of common stock from direct ownership to indirect ownership. These shares are now held by the Clarence Frank Bennett TTEE Bennett Living Trust Dated 3/12/2008, where Mr. Bennett serves as co-trustee alongside his spouse. Furthermore, the reporting period included the vesting of 15,000 Restricted Stock Units on January 15, 2026. These units were settled and paid out in whole shares of Ionis common stock.
The insider activity coincides with significant developments in Ionis Pharmaceuticals' clinical pipeline. The company recently reported that its CARDIO-TTRansform Phase 3 trial failed to meet its primary endpoint. This trial was designed to evaluate the efficacy of the drug eplontersen for the treatment of TTR cardiomyopathy. The outcome of this trial has triggered a series of adjustments in analyst sentiment.
Major financial institutions, including Jefferies, BofA Securities, TD Cowen, and Oppenheimer, have reduced their price targets for Ionis Pharmaceuticals. The revised price targets now range between $90 and $94. Despite these downward adjustments to valuation expectations, all four firms maintained a Buy or Outperform rating on the stock. Jefferies attributed the trial outcome to the strong market performance of Tafamidis, which may have impacted the trial's comparative metrics. BofA Securities noted that the results were unexpected given previous supportive data associated with TTR-silencers.
The clinical setback has also influenced the broader competitive landscape. Shares of Alnylam Pharmaceuticals and BridgeBio Pharma have seen significant increases. Both companies possess approved drugs for the same condition that Ionis was targeting in the failed trial. This market movement highlights the intense competition in the treatment of TTR cardiomyopathy. The current trading activity for Ionis Pharmaceuticals shows a closing price of 64.28, representing a decline of 20.18 or 23.89% from the previous close. After-hours trading indicates a slight recovery to 64.30.